<code id='FC3D58316E'></code><style id='FC3D58316E'></style>
    • <acronym id='FC3D58316E'></acronym>
      <center id='FC3D58316E'><center id='FC3D58316E'><tfoot id='FC3D58316E'></tfoot></center><abbr id='FC3D58316E'><dir id='FC3D58316E'><tfoot id='FC3D58316E'></tfoot><noframes id='FC3D58316E'>

    • <optgroup id='FC3D58316E'><strike id='FC3D58316E'><sup id='FC3D58316E'></sup></strike><code id='FC3D58316E'></code></optgroup>
        1. <b id='FC3D58316E'><label id='FC3D58316E'><select id='FC3D58316E'><dt id='FC3D58316E'><span id='FC3D58316E'></span></dt></select></label></b><u id='FC3D58316E'></u>
          <i id='FC3D58316E'><strike id='FC3D58316E'><tt id='FC3D58316E'><pre id='FC3D58316E'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:6566
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          How to fix cancer clinical trials' diversity problem
          How to fix cancer clinical trials' diversity problem

          Clockwisefromtopleft:STAT'sNicholasSt.Fleur(moderator);JudySewards,headofclinicaltrialexperienceatPf

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          Advances in CAR

          AdamFeuerstein,upperleft,moderatedapanelwith,clockwise,DavidChangofAllogeneTherapeutics,RachelHaurwi